Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
15 juil. 2024 10h29 HE
|
Sabin Vaccine Institute
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month. WASHINGTON, July 15, 2024 (GLOBE NEWSWIRE) -- Sabin Vaccine...
Global Impact, on behalf of the Advancing Health Online Initiative (AHO) and Gavi, The Vaccine Alliance, invests $12 million through the VaxSocial Initiative to implement innovative social media interventions to build vaccine confidence
01 mai 2024 10h34 HE
|
Global Impact
Geneva, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Global Impact, as fiscal sponsor for the VaxSocial Initiative, is pleased to announce the selection of seven organizations that will receive...
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
17 avr. 2024 08h00 HE
|
Evaxion Biotech
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
08 avr. 2024 10h00 HE
|
Curevo Vaccine
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...
Parexel Named “Best Contract Research Organization” at 17th Annual Vaccine Industry Excellence (ViE) Awards
04 avr. 2024 09h00 HE
|
Parexel International LLC
DURHAM, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
02 avr. 2024 07h00 HE
|
Evaxion Biotech
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
01 avr. 2024 16h01 HE
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...